Vitrolife AB is a leading global provider of medical devices and genetic testing services dedicated to the reproductive-health market. Founded in 1994, the company develops, manufactures, and distribu... Vitrolife AB is a leading global provider of medical devices and genetic testing services dedicated to the reproductive-health market. Founded in 1994, the company develops, manufactures, and distributes specialized products for in vitro fertilization (IVF) clinics, including sperm processing solutions, culture media, and advanced genetic testing to support fertility treatments worldwide. Its mission focuses on enabling IVF clinics to enhance treatment outcomes, helping patients achieve successful reproductive health results through high-quality, reliable solutions. Operating across three key geographical segments—EMEA, Americas, and APAC—with the majority of revenue from EMEA, Vitrolife AB emphasizes rigorous quality control, regulatory compliance (including CE marks and FDA clearance), and ongoing research and development in collaboration with universities and clinics. The company, headquartered in Gothenburg, Sweden, employs over 1,100 people and integrates sustainability practices, such as ISO 14001 certification for its facilities. As part of the Vitrolife Group, following the 2021 acquisition of Igenomix, it covers the entire reproductive-health journey, from embryo culture to genetic analysis, solidifying its role in advancing assisted reproduction technologies.
We reviewed Vitrolife's website and available disclosure materials for the 2023 reporting period and did not identify any reported Climate Targets data.
If you would like us to review newly published materials or reassess the most recent
disclosures, you can submit a data update request.